Patent intelligence · US
US 11559515
Indole compounds and analogues thereof
Indole compounds and analogues thereof
Patent details — US 11559515
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 24, 2023
- Expiration
- Jan 19, 2043
- Applicant
- BioCryst Pharmaceuticals, Inc.
- Claims
- 19
- CPC classes
- A61K, A61K31/416, A61P, A61P13/00
Quick answer
US 11559515 (Indole compounds and analogues thereof) is held by BioCryst Pharmaceuticals, Inc.. Status: granted. Granted Jan 24, 2023. Expires Jan 19, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BioCryst Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/416, A61P, A61P13/00, A61P13/10, A61P21/04
More from BioCryst Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12344585
Crystalline salts of a plasma kallikrein inhibitor
granted -
US 12162838
Human plasma kallikrein inhibitors
granted -
US 12121503
Antiviral treatments
granted -
US 12116346
Human plasma kallikrein inhibitors
granted -
US 12054492
Imidazole-containing inhibitors of ALK2 kinase
granted -
US 12043610
Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
granted -
US 11975003
Methods and compositions for treatment of Zika virus infection
granted -
US 11866418
Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
granted
Frequently asked questions
What is US patent 11559515?
US 11559515 (Indole compounds and analogues thereof) is held by BioCryst Pharmaceuticals, Inc.. Status: granted. Granted Jan 24, 2023. Expires Jan 19, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11559515?
BioCryst Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 72 pharmaceutical patents for this assignee.
When does US 11559515 expire?
Our index shows an expiration date of Jan 19, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.